Do rheumatoid arthritis patients have equal access to treatment with new medicines? Tumour necrosis factor-alpha inhibitors use in four European countries

Health Policy

Volumn 104, Issue 1, 2012, Pages 76-83

  Hoebert, Joëlle M ^a   Mantel Teeuwisse, Aukje K ^a   van Dijk, Liset ^b   Bijlsma, Johannes W J ^c   Leufkens, Hubert G M ^a  

^a UTRECHT UNIVERSITY   (Netherlands)

^b NETHERLANDS INSTITUTE FOR HEALTH SERVICES RESEARCH   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Access; Biologicals; Intercountry variation; Rheumatoid arthritis; TNFalpha inhibitors; Utilisation

Indexed keywords

ADALIMUMAB; ETANERCEPT; INFLIXIMAB;

ARTICLE; CONTROLLED STUDY; DATA ANALYSIS; DRUG UTILIZATION; HEALTH CARE; HEALTH CARE COST; HEALTH CARE POLICY; HEALTH CARE UTILIZATION; HUMAN; IRELAND; MEDICAL LITERATURE; NETHERLANDS; NORWAY; PORTUGAL; PRACTICE GUIDELINE; QUALITATIVE ANALYSIS; RHEUMATOID ARTHRITIS; RHEUMATOLOGY;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CULTURAL CHARACTERISTICS; DRUG UTILIZATION REVIEW; GUIDELINES AS TOPIC; HEALTH POLICY; HEALTH SERVICES ACCESSIBILITY; HUMANS; IMMUNOGLOBULIN G; IRELAND; NETHERLANDS; NORWAY; PORTUGAL; RECEPTORS, TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR-ALPHA;

EID: 83555164742     PISSN: 01688510     EISSN: 18726054     Source Type: Journal    
DOI: 10.1016/j.healthpol.2011.10.011     Document Type: Article

References (28)

1. Pucino F., Harbus P.T., Goldbach-Mansky R. Use of biologics in rheumatoid arthritis: where are we going?. American Journal of Health-System Pharmacy 2006, 63(18 Suppl. 4):S19-S41.
2. Goekoop-Ruiterman Y.P., de Vries-Bouwstra J.K., Allaart C.F., van Zeben D., Kerstens P.J.S.M., Hazes J.M.W., et al. Comparison of treatment strategies in early rheumatoid arthritis: a randomized trial. Annals of Internal Medicine 2007, 146(6):406-415.
3. Mottonen T., Hannonen P., Leirisalo-Repo M., Nissilä M., Kautiainen H., Korpela M., et al. Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial, FIN-RACo trial group. Lancet 1999, 353(9164):1568-1573.
4. Verstappen S.M., Bakker M.F., Heurkens A.H.M., van der Veen M.J., Kruize A.A., Geurts M.A., et al. Adverse events and factors associated with toxicity in patients with early rheumatoid arthritis treated with methotrexate tight control therapy: the CAMERA study. Annals of the Rheumatic Diseases 2009, 69(6):1044-1048.
5. Smolen J.S., Landewé R., Breedveld F.C., Dougados M., Emery P., Gaujoux-Viala C., et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Annals of the Rheumatic Diseases 2010, 69(6):964-975.
6. Kievit W., Adang E.M., Fransen J., Kuper H.H., van de Laar M.A., Jansen T.L., et al. The effectiveness and medication costs of three anti-tumour necrosis factor alpha agents in the treatment of rheumatoid arthritis from prospective clinical practice data. Annals of the Rheumatic Diseases 2008, 67(9):1229-1234.
7. Kobelt G, Kasteng F. Access to innovative treatments in rheumatoid arthritis in Europe. 2009 October [cited 2010 20 September]. Available from: http://www.comparatorreports.se/Access%2520to%2520RA%2520Treatments%2520October%25202009.pdf.
8. Stolk P., Belitser S.V., Leufkens H.G.M., Heerdink E.R. Variable access to clopidogrel in a harmonized EU market. Value in Health 2008, 11(5):989-995.
9. Lu C.Y., Ritchie J., Williams K.M., Day O.R. Recent developments in targeting access to high cost medicines in Australia. Australia and New Zealand Health Policy 2005, 2:28.
10. Emery P., Buch M. Treating rheumatoid arthritis with tumour necrosis factor alpha blockade. BMJ 2002, 324(7333):312-313.
11. Richards M. Extent and causes of international variations in drug usage. Secretary State of Health 2010.
12. Jonsson B., Kobelt G., Smolen J. The burden of rheumatoid arthritis and access to treatment: uptake of new therapies. European Journal of Health Economics 2008, 8(Suppl. 2):S61-S86.
13. Nolte E., Newbould J., Conklin A. International variation in the usage of medicines. A review of the literature 2010, RAND Corporation.
14. Miltenburger C, Günther OH, Justo N, Karampampa K, Texier-Richard B, Schweikert B. A survey of barriers to treatment access in rheumatoid arthritis in France, Germany, Italy, Spain and the UK. 2009 October 2009 [cited 2010 20 September]. Available from: http://www.comparatorreports.se/RA%2520Barrier%2520Report_FINAL_050110.pdf.
15. European Medicines Agency. EPAR Remicade [cited 2009 May]. Available from: http://www.emea.europa.eu/humandocs/Humans/EPAR/remicade/remicade.htm.
16. Smolen J.S., Steiner G. Therapeutic strategies for rheumatoid arthritis. Nature Reviews Drug Discovery 2003, 2(6):473-488.
17. European Medicines Agency. EPAR Humira [cited 2009 May]. Available from: http://www.emea.europa.eu/humandocs/Humans/EPAR/humira/humira.htm.
18. European Medicines Agency. EPAR Enbrel [cited 2009 May 22]. Available from: http://www.emea.europa.eu/humandocs/Humans/EPAR/enbrel/enbrel.htm.
19. Gesundheit österreich (GöG)/Austrian Health Institute, H.E.D. Pharmaceutical Pricing and Reimbursement Information - Country Reports. 2009 [cited 2010 August 22]. Available from: .
20. Fonseca J.E., Canhão H., Reis P., Santos M.J., Branco J., Quintal A., et al. Portuguese guidelines for the use of biological agents in rheumatoid arthritis. Acta Reumatologica Portuguesa 2010, 35(March (1)):95-98. [update].
21. Organisation for Economic Co-operation and Development. OECD Health Data 2010-Version: June 2010. 2009 [cited 2010 August]. Available from: http://www.irdes.fr/EcoSante/DownLoad/OECDHealthData_FrequentlyRequestedData.xls.
22. Guidelines for Prescribing TNFalpha Blockers in Adults with Rheumatoid Arthritis, Irish Society of Rheumatology.
23. Kwaliteitsinstituut voor de Gezondheidszorg CBO, Richtlijn: Diagnostiek en behandeling van reumatoïde artritis. 2009, Nederlandse Vereniging voor Reumatologie. p. 211.
24. World Health Organization. Collaborating Centre for Drug Statistics Methodology. ATC/DDD methodology [cited 2009 11 March]. Available from: http://www.whocc.no/atc_ddd_methodology/purpose_of_the_atc_ddd_system/.
25. World Health Organization. Collaborating Centre for Drug Statistics Methodology. DDD [cited 2009 10 March]. Available from: http://www.whocc.no/ddd/definition_and_general_considera/.
26. Ronning M., Blix H.S., Strøm H., Skovlund E., Andersen M., Vander Stichele R. Problems in collecting comparable national drug use data in Europe: the example of antibacterials. European Journal of Clinical Pharmacology 2003, 58(12):843-849.
27. World Health Organization. Collaborating Centre for Drug Statistics Methodology. ATC/DDD index [cited 2009 October]. Available from: http://www.whocc.no/atcddd/.
28. Eurostat. Population statistics [cited 2011 September]. Available from: http://epp.eurostat.ec.europa.eu/portal/page/portal/eurostat/home.